Company ProfilePremium

Aedifica SA

Company Profile Analysis

Ticker: AOO.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aedifica SA - Company showcase

Year Founded & Workforce

2005

Aedifica SA logo

Aedifica SA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aedifica SA Overview

Aedifica is a Brussels-based, internally managed healthcare real estate investment trust that owns and develops care homes, senior housing, specialised care properties and other healthcare-related real estate leased on very long contracts to professional care operators across Europe. Over two decades it has grown from a domestic mixed-use REIT into a pan-European healthcare specialist. Its 2026 absorption of Cofinimmo, then Belgium's largest listed REIT, doubled the group to a €12.5bn portfolio and made it Europe's largest listed healthcare-focused real estate company by property value. The model is defensive: rental income is overwhelmingly indexed, occupancy is near 100%, and leases average about 15 years. The investment case rests on structural ageing demographics, an undersupply of modern care beds and a disciplined development pipeline at yields above financing costs. The key tensions are leverage of about 43%, heavy refinancing needs in 2027–28, tenant credit concentration among a few large operators, and the integration of Cofinimmo's legacy office and pub portfolios.


Company's own description

In its standard boilerplate, Aedifica describes itself as a listed Belgian company that provides sustainable real estate to professional operators caring for people with care needs across Europe. It says it specialises in investing in high-quality European healthcare property with a focus on the care needs of elderly people, and that it aims to remain a leader in European listed real estate (company boilerplate, reproduced on investor data platforms, 2025–2026).

After the merger, the H1 2026 report frames the group as "Europe's leading healthcare REIT", with a €12.5bn portfolio of which €11.1bn is healthcare real estate in nine countries (H1 2026 report, 1 Sep 2026).

Independent characterisation

Aedifica is a pure landlord with an integrated development capability. It does not operate care services. Its value chain sits between capital markets (equity, bonds, bank debt) and care operators (commercial, non-profit and public). It creates value through:

  1. Acquisitions of standing assets let on long, mostly triple-net, indexed leases.

  2. Pre-let development and redevelopment with operators, delivering yields on cost above acquisition yields. The 2025 pipeline of €276m carried an average initial yield on cost of 6.5% (FY2025 results).

  3. Asset rotation, selling non-core or weaker assets and recycling capital. €98m was sold in 2024, and the whole Swedish portfolio plus other assets (31 properties, about €105m) was sold in H1 2025 (FY2024 results; H1 2025 report).

  4. Capital structure management, keeping debt-to-assets in the low 40s, a low average cost of debt (1.9–2.0%) and high hedging (88% at end-2025, per the FY2025 results presentation).

Revenue model

Revenue typeShare of revenueComment
Rental income from long leases (healthcare)≈100% pre-merger; ≈89% of portfolio value post-mergerMostly triple-net or double-net leases. In the UK, Finland, Ireland and Germany leases typically run 15–30 years with CPI-linked indexation (often capped or collared).
Rental income — offices (legacy Cofinimmo)Not separately disclosed in retrieved H1 2026 dataBrussels office portfolio inherited from Cofinimmo
Rental income — distribution networks / property of distribution networks (legacy Cofinimmo)Not separately disclosed in retrieved dataPub portfolio (Pubstone) and insurance agency network (Cofinimur I), inherited from Cofinimmo
Development / service incomeImmaterialDevelopments are capitalised, not sold
Product / licensing / subscription——

Customer types: private care operators (large listed and private groups such as Clariane, emeis and Attendo, which management benchmarks in its H1 2026 slides), regional operators, non-profit and public-sector entities (notably in Finland, Belgium and the Netherlands), and childcare operators (Finland).

End-markets: residential elderly care (nursing homes), assisted living / senior housing, specialised care (mental health, disability), primary care / medical centres (expanded via Cofinimmo), private clinics and rehabilitation (Cofinimmo legacy), childcare centres (Finland), and non-healthcare legacy segments (offices, pubs and insurance agencies).

Strategy

Stated strategy (themes, paraphrased)

  1. Healthcare focus: investment exclusively in European healthcare real estate, centred on elderly care (company boilerplate).

  2. Creating Europe's leading healthcare REIT through the Cofinimmo combination, with scale, diversification, cost synergies and cost-of-capital benefits (H1 2026 report).

  3. Pre-let development as the engine of organic growth at yields on cost above the portfolio yield (6.5% average on the 2025 pipeline).

  4. Asset rotation: disciplined disposal of non-core or underperforming assets (Sweden exit; €110m target for 2026).

  5. Balance-sheet discipline: debt-to-assets around 42–43%; diversified funding; BBB+ rating.

  6. Sustainability: net-zero ambition for the portfolio by 2050, EPC coverage, and support for operators in reducing portfolio emissions (Q3 2025 slides).

Initiatives in the last 24 months

InitiativeTimingDetail / targetStatus
Cofinimmo combinationMay 2025 to Jul 2026All-share exchange offer followed by legal mergerCompleted 1 Jul 2026
Synergy programme2026–2027At least €16m annual run-rate synergies during 2027; about €5–5.5m impact in 2026In progress (H1 2026)
Integration2,026Country leads appointed, IT harmonised, single platformIn progress
Competition-remedy divestmentsSeveral years from 2026About €300m of Belgian healthcare real estate to be soldCommitment (BCA clearance, Jan 2026)
Asset rotation 20262,026€110m target; €54m achieved by H1In progress
Investment programmeOngoing€531m programme at 30 Jun 2026; €195m new investments announced YTD (€84m in H1 plus €111m over summer)Ongoing
Refinancing2,026€620m inaugural syndicated facility for the combined group; €930m of long-term bank (re)financing contracted in H1 2026Completed in H1 2026
Development pipeline targetMedium term€500–750m pipeline ambition (per H1 2026 earnings call summary, Investing.com)Target
Strategic review of non-healthcare assetsn/vOffices and distribution networks inherited from CofinimmoNot formally announced in retrieved sources

Guidance / medium-term targets

ItemTargetSource
FY2026 rental income≈€656mH1 2026 earnings summary (Quartr)
FY2026 EPRA Earnings€436mH1 2026 report
FY2026 EPRA EPS€5.35 (+4% on FY2025's €5.15)H1 2026 report
FY2026 gross DPS€4.20 (+5%)Q1 and H1 2026 reports
Year-end 2026 debt-to-assets≈42%H1 2026 earnings summary
Leverage corridor42–43%H1 2026 call summary
Synergies≥€16m run-rate during 2027H1 2026 report

Pre-merger standalone guidance for FY2026 had been EPRA EPS of €5.20 (FY2025 results, Feb 2026). The upgrade to €5.35 reflects merger accretion.

Products & Services

Aedifica's "products" are real estate asset classes and lease formats. The catalogue below follows the company's facility-type and country segmentation.

Healthcare real estate

Product lineDescriptionTarget customerLease / pricing modelGeographyFlagship / notes
Elderly care homes (nursing homes)Purpose-built residential care facilities with 24/7 nursingCommercial and non-profit care operatorsLong triple-net leases (often 20–30 years in DE/UK/IE; 27-year emphyteutic or long leases in BE), CPI-indexedAll 9 countriesCore of the portfolio; with senior housing ≈86% of assets (FY2024)
Senior housing / assisted livingIndependent apartments with optional care servicesOperators; in some NL assets, residents directly (B2C model)Long leases; some B2C rents in NLBE, NL, DE, FINL shift towards B2C lifted rents in 2025 (FY2025 webcast)
Specialised care propertiesFacilities for mental health, disability and care for people with special needsPublic and non-profit operatorsLong leasesFI, UK, NL, BEExpanded via Hoivatilat (Finland)
Childcare / day-care centresChildren's day-care buildingsMunicipal and private childcare operatorsLong leasesFIInherited with Hoivatilat
Primary care / medical office (legacy Cofinimmo)Medical centres, GP practices and outpatient facilitiesHealthcare providersLong leasesBE, NL, IE, othersVia Cofinimmo (n/v detail)
Clinics and rehabilitation centres (legacy Cofinimmo)Acute and post-acute clinics, rehab and psychiatric clinicsHospital and clinic operatorsLong leasesDE, FR, BE, NLVia Cofinimmo (n/v detail)
Development and redevelopment programmePre-let new builds and extensions delivered to operatorsExisting and new tenantsYield on cost about 6.5% (2025 pipeline average)All markets€531m investment programme at 30 Jun 2026; €195m of new investments announced YTD to summer 2026

Non-healthcare (legacy Cofinimmo, post-1 July 2026)

Product lineDescriptionTenant / partnerStatus
Offices (Brussels)Office buildings mainly in Brussels CBD and decentralised areasCorporate and public tenantsNon-core to Aedifica's healthcare strategy; strategic intent (hold, reposition or sell) not explicitly confirmed in retrieved sources
PubstonePub estate in Belgium and the Netherlands leased to a brewer (AB InBev group)Brewer (single-tenant master lease)Legacy distribution network; n/v current treatment
Cofinimur IInsurance agency branch network in FranceInsurer (MAAF/Covéa group)Legacy distribution network; n/v current treatment

Financial "products" (capital-markets offering)

Aedifica shares (BEL 20), an optional stock dividend programme offered in past years, sustainability bonds and US private placement notes (including £180m USPP in 2021), and commercial paper backed by A-2 short-term rating (2026).

Financial Narrative

Sources: FY2021 and FY2022 annual results releases (23 Feb 2022; 16 Feb 2023); FY2024 annual results (19 Feb 2025); Aedifica website consolidated accounts (FY2023–FY2025 income statement; FY2022–FY2025 balance sheet), published 16 Feb 2026. All figures are in EUR millions unless stated. FY = calendar year.

Income statement

Notes:

  • The FY2024 release reports €234.6m as +7% year on year, which implies about €219m for FY2023.

  • The FY2022 EPRA NTA restatement is noted in 6.4.

  • 2021 EPRA EPS of €4.35 compares with €4.23 for the 2020 period.

Margins and growth

Rental income CAGR FY2021–FY2025: about 11.7% per year (derived: €232.1m to €361.0m over four years).

EPRA EPS CAGR FY2021–FY2025: about 4.3% per year (derived).

Commentary. Growth decelerated sharply from high teens in 2022–2023 to about 7% in 2024–2025. The early years were driven by large acquisition and development volumes (more than €800m invested in 2022). The later slowdown reflects a deliberate pivot, after interest rates rose in 2022–23, from external growth to asset rotation and balance-sheet protection. Like-for-like growth has stepped down from 4.2% (2022, peak inflation indexation) to 2.7% (2025) as CPI cooled.

Margins expanded consistently: the EPRA cost ratio fell from 15.4% to 13.5% between 2023 and 2025 because overheads stayed flat in absolute terms (€35.7m to €34.7m) while rents rose about 15%.

EPRA EPS dipped in 2024 (-1.8%), the only decline in the series. The cause was dilution from the 2023 capital increase (share capital rose from €1,006.9m to €1,203.6m in 2023) and higher interest costs, before growth resumed in 2025.

IFRS net profit is highly volatile because of non-cash revaluations. 2022 was boosted by property and hedge revaluations (€331.8m). 2023 almost wiped out IFRS earnings (€24.5m) on a €143.6m property devaluation and €50.9m of negative hedge revaluation. 2024–2025 recovered as valuations stabilised and then rose (+€75.4m in 2025).

The 2025 tax line jumped to €38.6m, mainly deferred tax on foreign revaluations (deferred tax liabilities rose from €133.2m to €159.6m). In addition, a €11.7m loss on disposals in 2025 was associated with the rotation programme, including the Swedish exit.

Balance sheet

Notes:

  • Current "other" financial debt (€484m at end-2025) is largely commercial paper. This explains the structurally negative working capital, which is typical for Belgian REITs and covered by unused committed credit lines (€673m headroom at end-2024).

  • Goodwill (mainly from the Hoivatilat acquisition) has been impaired every year, from €143.7m in 2022 to €59.7m in 2025.

Per-share NAV metrics

Source conflict: the FY2021 release reported an EPRA NTA of €76.05 at 31 Dec 2021, while the FY2022 release shows €72.78 for the same date (and NRV €85.10 versus €88.36; NDV €69.08 versus €72.35). This indicates a restatement of the 2021 comparatives, probably methodological (for example deferred tax treatment). Both values are noted, and the table above uses the originally published figures.

Cash flow

Aedifica has no share buyback programme (none identified). For a REIT with negligible maintenance capex on triple-net assets, EPRA Earnings is the closest proxy for recurring cash generation. Available capital-allocation proxies:

FY2025 divestments included the Swedish exit; H1 2025 disposals were 31 properties for about €105m. The 2026 asset-rotation target is €110m, of which €54m had been achieved by H1 2026 (H1 2026 earnings summary).

Ratios (derived from primary data)

Company-reported figures: net debt/EBITDA of 8.5x (FY2024) and 7.8x (FY2025); interest coverage of 6.2x (FY2024) (MNI note; FY2025 webcast). The cash conversion cycle is not meaningful for a landlord.

Commentary. Recurring returns on equity of about 6.5–6.7% sit close to the EPRA initial yield, which is typical of a moderately geared, core-plus healthcare landlord. The deleveraging from 43.6% debt-to-assets in 2022 to 40.8% in 2025 came alongside rising earnings, so the balance-sheet discipline did not sacrifice growth. Net debt/EBITDA fell below 8x for the first time in the series in 2025.

Post-merger interim figures

Point-in-time metrics:

  • At 31 Mar 2026: EPRA NTA €80.34, EPRA LTV 39.9%, EPRA NIY 5.6%, EPRA vacancy 0.8% (Q1 2026 report, Dutch version).

  • At 30 Jun 2026: EPRA NTA €77.82, after the May 2026 dividend (Saxo, citing H1 2026). EBIT margin 86.6% and average cost of debt 1.9% in H1 2026.

Sources: H1 2025 and H1 2026 reports; Q1 2026 report.

Interpretation. The transaction was EPS-accretive from the first half (+5%) despite issuing about 45 million new shares. Some metrics deteriorated mechanically because the Cofinimmo portfolio is shorter-dated and includes offices: WAULT fell from 18 to 15 years, occupancy from about 100% to 99.1%, EPRA vacancy from 0.1% to 0.8%, and the cost ratio rose to 15.0%.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

Segment (rental income, EUR Mn)FY2023FY2024FY2025

Total group rental income

314.2338.1361.0

Revenue by Segment

Country (fair value, EUR Mn)2021Q12025

Belgium

1,1601,256

Germany

6671,168

Netherlands

534666

United Kingdom

7391,248

Finland

7451,223

Ireland

26432

Spain

—22

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Rental income (EUR Mn)

314.2338.1361.0

Operating result before result on portfolio (EUR Mn)

265.8290.3312.1

Operating margin (%)

84.685.886.4

Rental income YoY growth (%)

—7.66.8

Portfolio Component Details

Portfolio componentValue (EUR Bn, 30 Jun 2026)Share (%)Content

Healthcare real estate

11.1

≈89

924 properties, 80,000+ end users, 9 countries

Non-healthcare (offices + distribution networks)

≈1.4 (derived)

≈11

Legacy Cofinimmo Brussels offices; Pubstone pub estate (BE/NL); Cofinimur I (FR)

Group total

12.5

100

—

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Rental income (EUR Mn)

232.1273.1314.2338.1361.0

Net rental income (EUR Mn)

——313.0338.0360.5

Property operating result — gross profit proxy (EUR Mn)

——301.7326.2348.6

Overheads (EUR Mn)

——35.735.134.7

Operating result before result on portfolio — EBITDA proxy (EUR Mn)

——265.8290.3312.1

Change in fair value of investment properties (EUR Mn)

——-143.615.275.4

Operating result incl. portfolio — EBIT (EUR Mn)

——95.2275.6348.2

Net interest charges (EUR Mn)

——45.046.750.2

Change in fair value of financial instruments (EUR Mn)

——-50.9-18.7-9.6

Profit before tax (EUR Mn)

——-3.1205.4283.7

Tax expense, negative = credit (EUR Mn)

——-25.60.338.6

Net profit attributable to owners (EUR Mn)

—331.824.5204.8244.4

EPRA Earnings (EUR Mn)

151.5181.4—234.6244.8

EPRA Earnings per share (EUR)

4.354.765.024.935.15

IFRS basic EPS (EUR)

——0.564.315.14

IFRS diluted EPS (EUR)

——0.564.315.14

Gross dividend per share (EUR)

3.403.703.803.904.00

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Rental income growth YoY (%)

—17.715.07.66.8

Like-for-like rental growth (%)

—4.2—3.32.7

Gross margin — property operating result / rental income (%)

——96.096.596.6

EBITDA-proxy margin (%)

——84.685.886.4

EPRA Earnings margin (%)

65.366.4—69.467.8

Net margin — owners' profit / rental income (%)

—121.57.860.667.7

EPRA EPS growth YoY (%)

2.89.45.5-1.84.5

EPRA cost ratio incl. vacancy (%)

——15.414.213.5

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR Mn)

—6,085.56,176.86,463.86,477.1

Investment properties (EUR Mn)

—5,619.75,790.46,117.96,215.6

Assets held for sale (EUR Mn)

—84.058.2100.269.6

Cash and equivalents (EUR Mn)

—13.918.318.522.0

Non-current financial debt (EUR Mn)

—2,017.31,958.82,065.21,933.7

Current financial debt (EUR Mn)

—435.2321.5448.4551.3

Total financial debt (EUR Mn)

—2,452.42,280.32,513.62,485.0

Net financial debt (EUR Mn)

—2,438.52,262.02,495.22,463.0

Total equity (EUR Mn)

—3,289.33,580.93,648.13,669.3

Equity attributable to owners (EUR Mn)

—3,282.83,575.93,643.03,663.7

Goodwill (EUR Mn)

—143.7117.687.459.7

Intangible assets (EUR Mn)

—1.91.71.00.6

Deferred tax liabilities (EUR Mn)

—164.1138.7133.2159.6

Working capital — current assets minus current liabilities (EUR Mn)

—-392.3-280.0-355.8-485.0

Debt-to-assets ratio, regulatory (%)

42.643.6—41.340.8

Real estate portfolio (EUR Bn)

—5.7—6.26.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Per-Share Data and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

EPRA NTA per share (EUR)

76.0579.7174.1876.6378.40

EPRA NRV per share (EUR)

88.3691.7484.1786.4687.09

EPRA NDV per share (EUR)

72.3583.9275.4177.1977.73

EPRA Net Initial Yield (%)

—4.95.35.35.6

EPRA vacancy rate (%)

0.50.40.10.10.1

Key Financials and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Development projects delivered (EUR Mn)

—295—29796

Divestments (EUR Mn)

———98—

Dividend payout ratio on EPRA EPS (%)

78.277.775.779.177.7

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE — owners' profit / average owners' equity (%)

—0.75.76.7

ROE on EPRA Earnings — recurring (%)

——6.56.7

ROA — owners' profit / average assets (%)

—0.43.23.8

Pre-tax ROIC — EBITDA proxy / (equity + net debt) (%)

—4.54.75.1

Current ratio (x)

0.260.310.320.22

Debt / equity (x)

0.750.640.690.68

Net debt / EBITDA proxy (x)

—8.58.67.9

Interest coverage — EBITDA proxy / net interest (x)

—5.96.26.2

Asset turnover — rental income / average assets (%)

—5.15.35.6

Key Financials and Per-Share Data

MetricH1 2025H1 2026

Rental income (EUR Mn)

180.8292.3

EPRA Earnings (EUR Mn)

123.3189.9

EPRA EPS (EUR)

2.592.71

Like-for-like rental growth (%)

3.01.7

Occupancy (%)

100.099.1

WAULT (years)

1815

Debt-to-assets (%)

42.442.7

Real estate portfolio (EUR Bn)

6.212.5

Key Financials and Per-Share Data (Quarterly)

MetricQ1 2025Q1 2026

EPRA Earnings (EUR Mn)

62.674.5

EPRA EPS (EUR)

1.321.32

EPRA cost ratio incl. vacancy (%)

14.115.0

Revenue by Region

Region (rental income, EUR Mn)FY2023FY2024FY2025

Total

314.2338.1361.0

Revenue by Region (%)

Country (% of portfolio fair value)2021Q12025

Belgium

30.420.3

Germany

17.518.9

Netherlands

14.010.8

United Kingdom

19.420.2

Finland

19.519.8

Ireland

0.77.0

Region Overview

RegionTrendDriver

Ireland

Fastest growing (from €26m in 2021 to €432m in 2025)

New-build nursing homes with long leases into an undersupplied, fragmented market; development pipeline

Germany

Strong growth (+75% fair value 2021–2025)

Azurit (€245m) and other portfolios; operator stress in the German market has been a watch point

United Kingdom

Strong growth (+69%)

Bolt-on acquisitions and developments; UK identified as a growth focus in 2024 (MNI)

Finland

Growth (+64%)

Hoivatilat development engine (care homes, childcare)

Belgium

Slowest growing / declining share

Mature home market. Post-merger Belgium becomes dominant again (Cofinimmo was Belgium-centric), and the competition remedy requires about €300m of Belgian divestments over several years

Sweden

Exited (Q1 2025)

Asset rotation: sub-scale, non-core

Spain

Marginal (€22m)

Small legacy exposure; Cofinimmo adds further Spanish assets

France and Italy

New since March 2026

Entered via Cofinimmo

Valuation Snapshot

MetricValueSource

Last close

€62.95 (16 Oct 2026)

Trivano

52-week range (to Sep 2026)

€59.50 – €80.05

MarketScreener

YTD 2026

≈-7% (derived from ≈€67.5 at the start of the year)

MarketScreener (-2.5% YTD at €65.80 on 10 Sep 2026)

1-year / 3-year / 5-year total return

n/v

—

Valuation Multiples

MultipleAedificaBasis

P / EPRA Earnings 2026E

11.8x

€5.35 guidance

P / EPRA NTA

0.81x (≈19% discount)

€77.82 NTA at 30 Jun 2026

Dividend yield 2026E

6.7%

€4.20 DPS

P/E 2026E (IFRS, consensus)

8.0x

MarketScreener (includes revaluations)

EV/Sales 2026E

15.4x

MarketScreener

EV/EBITDA 2026E

≈17–18x (derived from EV of about €10.5bn and EBITDA of about €560–570m implied by an ~86% margin on €656m rent)

Derived

Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Gross DPS (EUR)

3.403.703.803.904.004.20

Credit Ratings

AgencyLong-termShort-termOutlookDate

S&P Global

BBB+

A-2

Stable

Upgraded Mar 2026; reconfirmed in H1 2026

Moody's

Not rated

———

Fitch

Not rated

———

Capital Markets

ItemValue

Debt-to-assets

42.7% (seasonal, after dividend payment)

Undrawn committed lines

€1,487m

Average cost of debt including fees

1.9%

Long-term bank (re)financing in H1 2026

€930m, including a €620m syndicated loan

Maturities 2027–2028

≈€2.2bn

Hedge ratio

≈88% (end-2025, standalone)

Encumbered assets

≈4% of assets (FY2024 standalone)

Analyst Conclusions

Management guidance (FY2026)

  • EPRA Earnings €436m, or €5.35 per share (+4%)

  • Rental income about €656m

  • DPS €4.20 (+5%)

  • Year-end debt-to-assets about 42%

  • Synergies of €5–5.5m in 2026, reaching at least €16m run-rate during 2027

MarketScreener's forward data imply a 2027 dividend yield of about 6.5% at September prices, consistent with mid-single-digit DPS growth.

Bull case

  1. Full-year synergies plus mechanical consolidation drive another step-up in 2027 EPRA EPS. €16m of synergies alone is roughly €0.17 per share on about 92.6m shares (derived), or about 3% accretion, before pipeline growth.

  2. NAV discount compression. At about 0.81x EPRA NTA and a 6.7% yield, the stock prices in a negative scenario that is inconsistent with 99% occupancy, a 15-year WAULT and a BBB+ balance sheet.

  3. Non-core disposals (offices, pubs, the €300m remedy) executed near book value would cut leverage towards 40%, make the portfolio purely healthcare, and could support re-rating to peer premiums.

Bear case

  1. Refinancing at higher rates. Rolling about €2.2bn of 1.9% debt in 2027–28 into a higher-rate environment could erase much of the synergy gain.

  2. Operator stress. Margin pressure at large European operators could force rent cuts or re-lettings, especially in the UK, Germany and France.

  3. Disposal and valuation risk. Forced Belgian sales and a weak office market could lead to book losses and higher LTV. The 2023 experience showed how quickly valuations can move (-€143.6m in one year).

Key catalysts and monitorables (next 12 months)

Date / periodCatalyst
18 Nov 2026Q3 2026 results: synergy tracking, leverage, rent cover
Feb 2027FY2026 results and FY2027 guidance (first full combined year)
2,027Progress on refinancing of the 2027–28 maturities and any bond issuance
2026–27Announcement of the office / distribution-network strategy
OngoingExecution of the €300m Belgian remedy disposals
OngoingLike-for-like rental growth (1.7% in H1 2026) as indexation fades
May 2027Payment of the €4.20 dividend
OngoingECB rate path and the 10-year Bund yield

Analyst verdict

Aedifica has spent twenty years building a disciplined, internally managed healthcare property platform. In 2026 it completed the transaction that defines its next decade. The numbers so far support the strategic logic. EPRA EPS rose 5% in the first half despite issuing about 45 million shares, management confirmed guidance of €5.35, and the dividend rises 5% to €4.20. S&P upgraded the credit rating to BBB+, and the group refinanced €930m of bank debt in a single half-year while keeping its average cost of debt at 1.9%. On operating metrics such as cost ratio, margin and occupancy, Aedifica remains best-in-class among European healthcare landlords.

The market's scepticism is nonetheless rational. The shares trade at about 81% of EPRA NTA and about 12x 2026 recurring earnings, and they have fallen about a fifth from their 52-week high. Three questions explain the discount. First, can the 1.9% cost of debt survive the 2027–28 refinancing wall of about €2.2bn? Second, will management convert roughly €1.4bn of non-healthcare legacy assets and €300m of mandated Belgian disposals into capital without value leakage? Third, are tenant rent covers robust enough for a sector whose largest operators remain under financial pressure?

Our assessment is that Aedifica's lease security (15-year WAULT, 99% occupancy, CPI indexation) and its scale-driven synergies give it more room to absorb higher refinancing costs than the valuation implies. The 6.7% prospective yield is well covered by a payout of about 78%. The investment case therefore hinges less on growth than on execution: delivering the €16m synergy run-rate, presenting a credible non-core disposal plan, and keeping leverage within the 42–43% corridor. Investors who believe management can do so are being paid a substantial yield while they wait. Those who expect a renewed rise in long-term rates should wait for the FY2026 results and the 2027 refinancing plan before committing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenureBackgroundAgeSource

Stefaan Gielens

CEO; Managing / Executive Director; chairs Executive Committee; member of Investment Committee

CEO since 1 Feb 2006; board since 2006

Master of Law and postgraduate certificate in real estate (KU Leuven); Brussels Bar lawyer 1989–94; KBC Group roles 1994–2005 including Managing Director of Almafin Real Estate and head of real estate management at KBC Bank/KBC Real Estate

Born 1965 (≈61)

Company CV (June 2026)

Ingrid Daerden

Chief Financial Officer

n/v start date

Financial career in Belgian and international real estate and telecom groups; represented Aedifica on Cofinimmo's board after March 2026

n/v

Cofinimmo committees page; Aedifica releases (CFO contact)

Delphine Noirhomme

Investor Relations contact

n/v

—

n/v

Aedifica releases

Other Executive Committee members

Newly composed Executive Committee effective at the legal merger (1 Jul 2026), combining Aedifica and Cofinimmo executives

From 1 Jul 2026

—

n/v

Q1 and H1 2026 reports

Board of Directors

NameRoleSinceNotes

Jean Hilgers

Independent Chair (from 1 Jul 2026); Chair of the Nomination & Remuneration Committee; member of the Audit & Risk Committee

Board since Mar 2026

Master in economics (UCLouvain; Chair of its board from 2007); long executive career at the National Bank of Belgium; board roles at the BIS, ING Belgium and AG Insurance; appointed Chair of Wallonie Entreprendre and Cofinimmo in 2025

Serge Wibaut

Director; Chair until 30 Jun 2026

n/v

Remains on the board after handing over the chair

Stefaan Gielens

Executive Director (CEO)

2006

Only executive director on the post-transaction board

Four further Cofinimmo independents

Independent Directors (co-opted March 2026)

Mar 2026

Five Cofinimmo directors joined in total under the transaction agreement; names other than Hilgers n/v

Remaining legacy Aedifica non-executives

Directors

various

n/v

Major Shareholders

HolderStakeSource

Free float

≈98.6%

MarketScreener (Sep 2026)

Top 10 institutional holders

No controlling shareholder exists.

—

Insider ownership

Low (single-digit basis points; n/v exact figure)

—

Competitive Landscape

Key Competitors

CompetitorListing / typeOverlap with AedificaRelative positioning

Care Property Invest

Euronext Brussels REIT

Belgian, Dutch and Spanish care homes

Much smaller; Belgian-centric

Primary Health Properties (enlarged by combination with Assura in 2025, n/v completion detail)

LSE REIT

UK and Irish primary care

Primary care rather than care homes; adjacent

Target Healthcare REIT

LSE REIT

UK care homes

Pure UK; smaller

Impact Healthcare REIT

LSE REIT

UK care homes

Pure UK; smaller

Welltower

NYSE REIT

UK seniors housing

Global giant; competes for UK assets

Ventas

NYSE REIT

UK seniors housing

Large; selective UK exposure

Praemia Healthcare (formerly Icade Santé)

Unlisted vehicle (France)

Clinics, nursing homes in France, Italy, Germany, Spain, Portugal

Major continental competitor for clinic and care assets

Hemsö

Unlisted (Sweden; listed bonds)

Nordic and German social infrastructure

Strong in the Nordics and Germany

Primonial REIM / Praemia REIM funds

Unlisted funds

Pan-European healthcare

Large capital pools bidding for assets

Aberdeen / AXA IM Alts / Swiss Life healthcare funds

Unlisted funds

Pan-European care homes

Capital competitors

Omega Healthcare / Sabra

NYSE REITs

UK care-home portfolios

US capital competing in the UK

Peer Comparison FY2025

Metric (latest FY)AedificaCare Property InvestTarget Healthcare REITWelltower

Revenue

€361.0m (FY2025); ≈€656m guided FY2026

n/v

n/v

n/v

Revenue growth

6.8% (FY2025)

n/v

n/v

n/v

Operating margin

86.4%

n/v

n/v

n/v

R&D intensity

0%0%0%0%

Portfolio

€12.5bn (Jun 2026)

n/v

n/v

n/v

Company Snapshot

2005

Founded

Brussels, Belgium

Headquarters

SWOT Analysis

Strengths

  • Scale leadership: €12.5bn portfolio; €11.1bn healthcare across 924 properties (H1 2026)
  • Earnings resilience: EPRA EPS rose from €4.35 (2021) to €5.15 (2025) through a rate shock; only one down year (2024, -1.8%)
  • Margin efficiency: EPRA cost ratio fell from 15.4% (2023) to 13.5% (2025); operating margin 86.4%
  • Lease security: WAULT of 15 years and 99.1% occupancy (H1 2026); vacancy 0.1% pre-merger
  • Funding strength: S&P BBB+ / A-2 (Mar 2026); 1.9% cost of debt; €1,487m undrawn headroom (H1 2026)
  • Accretive M&A execution: H1 2026 EPRA EPS +5% despite about 45m new shares issued
  • Dividend track record: DPS rose every year from €3.40 (2021) to €4.20 proposed (2026); payout about 76–79%

Weaknesses

  • Leverage at the upper end of the target range: 42.7% debt-to-assets (Jun 2026) versus 40.8% (Dec 2025)
  • Refinancing concentration: About €2.2bn to refinance in 2027–28 (H1 2026 call)
  • Non-core legacy assets: About €1.4bn of offices and distribution networks dilute the healthcare focus (derived from H1 2026)
  • Lease-profile dilution: WAULT 18 to 15 years and occupancy 100% to 99.1% after the merger
  • Goodwill impairments: Goodwill fell from €143.7m (2022) to €59.7m (2025), signalling that the Hoivatilat premium has not been recovered
  • Structurally negative working capital and short-term funding reliance: Current financial debt of €551m including €484m commercial paper (FY2025)

Opportunities

  • Synergy upside: At least €16m run-rate in 2027, against about €5–5.5m in 2026
  • Development pipeline at an accretive spread: €531m programme; 6.5% yield on cost versus 1.9% cost of debt
  • Recycling of non-core assets: Office and pub disposals could fund healthcare growth and lower leverage
  • New markets via Cofinimmo: France and Italy added (H1 2026)
  • NAV discount closure: Shares at €62.95 versus EPRA NTA of €77.82, about a 19% discount (derived)
  • Demographics: Ageing data highlighted across all nine countries (H1 2026 slides, Eurostat)

Threats

  • Rates: De Tijd (Sep 2026) flags higher rates raising the bar for real estate shares; the stock fell from €80.05 (52-week high) to €62.95
  • Operator credit: Management benchmarks the H1 2026 results of Clariane, emeis and Attendo, showing the sensitivity to tenant health
  • Forced disposals: €300m Belgian remedy could crystallise sales at weak prices
  • Valuation yields: The 2023 devaluation (-€143.6m) shows the sensitivity
  • Regulatory and political scrutiny of care: Post-Orpea reforms in France and Belgium (sector-level)
  • Integration risk: Cofinimmo's board itself flagged significant execution risk in May 2025

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 May 2025Aedifica approaches Cofinimmo with an exchange-offer proposal Cofinimmo releases listStart of the transformational deal
9 May 2025Cofinimmo board unanimously rejects the terms as undervaluing the company and carrying execution risk La Libre BelgiqueHostile phase; Aedifica declines to raise its terms
13 May 2025Cofinimmo publishes a status update on discussions Cofinimmo releases listNegotiations open
3 Jun 2025Agreement reached at 1.185x Cofinimmo releases list; LaingBuissonDeal becomes recommended
Jun 2025Aedifica shareholders approve the capital increase needed for the offer Q3 2025 slidesRemoves financing condition
18 Jul 2025Update on the Belgian Competition Authority (BCA) process Cofinimmo releases listAntitrust becomes the critical path
30 Jul 2025H1 2025 results: EPRA EPS €2.59 (+4%); S&P places BBB on CreditWatch positive H1 2025 reportStandalone strength
H1 2025Exit from Sweden; 31 properties sold for ≈€105m; €38m Finnish acquisition H1 2025 reportPortfolio focus
30 Sep 2025Further BCA progress update Cofinimmo releases listTimeline extended
28 Oct 2025Q3 2025 results; Dutch and German competition approvals obtained Q3 2025 slidesTwo of three approvals secured
Jan 2026BCA conditional clearance with ≈€300m Belgian divestment remedy Parqet summaryUnlocks the offer
29 Jan 2026Prospectus and response memorandum published Cofinimmo releases listOffer launched
30 Jan 2026Acceptance period opens (to 2 Mar) Parqet summary—
13 Feb 2026FY2025 results: EPRA EPS €5.15 (above budget); DPS €4.00 confirmedStrong base year
3 Mar 202679.57% of Cofinimmo tendered; no reopening of the offer manda.beControl achieved
10 Mar 2026Settlement; 35.9m new shares; new board with five Cofinimmo independents Aedifica releaseGovernance reset
Mar 2026S&P upgrades to BBB+ (stable), A-2 short-term Q1 2026 reportLower funding cost
Q1 2026€150m new long-term bank financing; €50m new investments (5 projects) Q1 2026 reportFunding and pipeline
30 Apr 2026Merger proposal filed; EGMs convened Aedifica releasePath to full integration
19 May 2026FY2025 dividend €4.00 paid (including to new shares) manda.beIncome delivery
19 May 2026Q1 2026 results: EPRA Earnings €74.5m (+19%); FY2026 DPS €4.20 proposed Q1 2026 reportFirst consolidated quarter
12 Jun 2026Aedifica EGM approves the merger (more than 99.99% in favour; 54.24% of shares represented) Zonebourse/FortuneoShareholder approval
30 Jun 2026Cofinimmo EGM approves the merger; last trading day of Cofinimmo shares Cofinimmo releases list—
1 Jul 2026Merger effective; Cofinimmo delisted; 9.16m shares issued; Jean Hilgers becomes Chair Merger completion releaseEnd of the transaction
Summer 2026€111m of additional investments announced H1 2026 reportPipeline replenishment
1 Sep 2026H1 2026: EPRA EPS €2.71 (+5%); guidance €5.35; €620m syndicated loan; €2.2bn refinancing need for 2027–28 flagged H1 2026 report; earnings summariesAccretion confirmed; leverage watch
16 Oct 2026Shares at €62.95, near the bottom of the 52-week range TrivanoMarket caution on rates and leverage
18 Nov 2026 (scheduled)Q3 2026 interim results Investing.com calendarNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Belgium rose from EUR 1,160 Mn in 2021Q1 to EUR 1,256 Mn in 2025.
Aedifica SA — Revenue by Segment
Series (EUR Mn)2021Q12025
Belgium1,1601,256
Germany6671,168
Netherlands534666
United Kingdom7391,248
Finland7451,223
Ireland26432
Spain—22

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.